Swedish Orphan Biovitrum
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
SOBI | ST
Overview
Corporate Details
- ISIN(s):
- SE0000872095 (+51 more)
- LEI:
- 549300124Y3MQI87PT35
- Country:
- Sweden
- Address:
- Tomtebodavagen 23A, 112 76 Stockholm
- Website:
- https://www.sobi.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-21 13:00 |
Regulatory News Service
Förändring i Sobis styrelse
|
Swedish | 132.4 KB | ||
| 2025-10-21 13:00 |
Board/Management Information
Change in the Sobi Board of Directors
|
English | 98.8 KB | ||
| 2025-10-20 08:00 |
Quarterly Report
|
Swedish | 3.8 MB | ||
| 2025-10-20 08:00 |
Quarterly Report
|
English | 4.1 MB | ||
| 2025-10-19 20:30 |
Earnings Release
Sobi meddelar reviderade helårsutsikter och tidigarelägger publiceringen av del…
|
Swedish | 206.4 KB | ||
| 2025-10-19 20:30 |
Earnings Release
Sobi announces revised full year outlook and advances publication of the Q3 202…
|
English | 174.2 KB | ||
| 2025-09-30 08:00 |
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
|
English | 137.5 KB | ||
| 2025-09-30 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
|
Swedish | 126.9 KB | ||
| 2025-08-29 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
|
Swedish | 100.2 KB | ||
| 2025-08-29 08:00 |
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
|
English | 97.9 KB | ||
| 2025-08-21 12:35 |
Share Issue/Capital Change
Sobi has completed issues of class C shares
|
English | 151.8 KB | ||
| 2025-08-21 12:35 |
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
|
Swedish | 151.6 KB | ||
| 2025-07-16 08:00 |
Quarterly Report
|
Swedish | 4.1 MB | ||
| 2025-07-16 08:00 |
Earnings Release
|
English | 4.1 MB | ||
| 2025-07-15 19:15 |
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
|
English | 138.4 KB |
Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Swedish Orphan Biovitrum
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-05-21 | Daniel Rankin | Other | Other | 2,954 | 440,146.00 SEK |
| 2021-05-10 | Guido Oelkers | Other | Buy | 5,059 | 700,115.01 SEK |
| 2021-05-10 | Guido Oelkers | Other | Buy | 22,112 | 3,058,266.50 SEK |
| 2021-05-10 | Guido Oelkers | Other | Buy | 1,520 | 210,225.12 SEK |
| 2021-05-10 | Guido Oelkers | Other | Buy | 113 | 15,639.20 SEK |
| 2021-05-10 | Guido Oelkers | Other | Buy | 169 | 23,368.48 SEK |
| 2021-05-10 | Guido Oelkers | Other | Buy | 1,703 | 235,536.82 SEK |
| 2021-03-10 | Paula Treutiger | Other | Buy | 700 | 102,683.00 SEK |
| 2021-03-08 | Norbert Oppitz | Other | Buy | 2,500 | 347,662.50 EUR |
| 2021-03-05 | Helena Saxon | Other | Buy | 4,500 | 619,200.00 SEK |
Peer Companies
